Hard for Eli Lilly to move significantly higher from here in the short-term: Kessef Capital's Yaffee

Our next guest says potentially strong data could put pressure on Lily shares. For more, let's bring in Kessive Capital managing director Len Yaffy. Len, great to have you with us. Good to see you.>> Thank you so much. >> So, we're expecting a couple of readouts on Marit Amgen's drug. Len, so what what's the scenario here.The the data is good. And what do you characterize as good and what does that mean. I think the key with maritide and this is part two of a phase two study is what is the incidence if we l ...